CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics Announces Closing of Public Offering of Common Stock

28 May 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of Public Offering of Common Stock

22 May 2024 22:30:50 By Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Public Offering of Common Stock

22 May 2024 15:02:00 By Nasdaq GlobeNewswire

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

22 May 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

17 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

15 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

13 May 2024 08:33:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

13 May 2024 08:33:00 By Nasdaq GlobeNewswire

Cytokinetics Reports First Quarter 2024 Financial Results

08 May 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Hold Annual Meeting of Stockholders

07 May 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

29 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce First Quarter Results on May 8, 2024

24 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

10 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

05 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

05 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

01 Apr 2024 15:00:00 By Nasdaq GlobeNewswire